Kantonsspital St.Gallen
login

EVOKE

Ansgar Felbecker

abstract A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
This study is done to find out whether semaglutide has a positive effect on early Alzheimer's disease.
Participants will either get semaglutide or placebo - which treatment participants get is decided by an equal chance.
The study will last for up to 173 weeks (about 3 years and 4 months). Participants will have 17 clinic visits and 1 phone call with the study doctor.
Participants must have a study partner, who is willing to take part in the study.
   
type of project clinical studies
status ongoing - recruiting phase
start of project 2021
end of project 2024
responsible person Felbecker, Ansgar